Acute suppurative terminal cholangitis: Clinical characteristics of a new subtype of acute cholangitis.

Acute cholangitis Acute suppurative terminal cholangitis Diagnosis Gram-negative bacterial infections Treatment

Journal

Hepatobiliary & pancreatic diseases international : HBPD INT
ISSN: 1499-3872
Titre abrégé: Hepatobiliary Pancreat Dis Int
Pays: Singapore
ID NLM: 101151457

Informations de publication

Date de publication:
18 Jan 2023
Historique:
received: 10 02 2022
accepted: 09 01 2023
entrez: 23 1 2023
pubmed: 24 1 2023
medline: 24 1 2023
Statut: aheadofprint

Résumé

Acute suppurative terminal cholangitis (ASTC) is rarer than acute obstructive cholangitis and is not well studied. To explore this subtype of acute cholangitis, we described our clinical experience with ASTC. We performed a retrospective review of patients with ASTC admitted to our center from September 2014 to August 2020. We analyzed their clinical characteristics, including etiology, clinical manifestations, imaging features, treatment and prognosis. A total of 32 ASTC patients were included in the analysis. The majority of the patients had a history of biliary operations, and clinical manifestations were occult and atypical. The positive rate of bacterial culture was 46.9%. All the patients had typical imaging features on computed tomography and magnetic resonance imaging. Treatment with effective antibiotics was provided as soon as diagnosis was established. After treatment, most patients had a good outcome. Elevated levels of total bilirubin, aspartate aminotransferase, procalcitonin and gamma-glutamyltransferase were the characteristics of critically ill patients and were associated with relatively poor prognosis. Our results demonstrated that ASTC should be recognized as a new subtype of acute cholangitis, and that earlier diagnosis and more personalized treatments are needed.

Sections du résumé

BACKGROUND BACKGROUND
Acute suppurative terminal cholangitis (ASTC) is rarer than acute obstructive cholangitis and is not well studied. To explore this subtype of acute cholangitis, we described our clinical experience with ASTC.
METHODS METHODS
We performed a retrospective review of patients with ASTC admitted to our center from September 2014 to August 2020. We analyzed their clinical characteristics, including etiology, clinical manifestations, imaging features, treatment and prognosis.
RESULTS RESULTS
A total of 32 ASTC patients were included in the analysis. The majority of the patients had a history of biliary operations, and clinical manifestations were occult and atypical. The positive rate of bacterial culture was 46.9%. All the patients had typical imaging features on computed tomography and magnetic resonance imaging. Treatment with effective antibiotics was provided as soon as diagnosis was established. After treatment, most patients had a good outcome. Elevated levels of total bilirubin, aspartate aminotransferase, procalcitonin and gamma-glutamyltransferase were the characteristics of critically ill patients and were associated with relatively poor prognosis.
CONCLUSIONS CONCLUSIONS
Our results demonstrated that ASTC should be recognized as a new subtype of acute cholangitis, and that earlier diagnosis and more personalized treatments are needed.

Identifiants

pubmed: 36690523
pii: S1499-3872(23)00001-2
doi: 10.1016/j.hbpd.2023.01.001
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2023 First Affiliated Hospital, Zhejiang University School of Medicine in China. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Competing interest No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.

Auteurs

Rong-Tao Zhu (RT)

Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China; Zhengzhou Key Laboratory of Hepatobiliary and Pancreatic Diseases, Zhengzhou 450052, China; Institute of Hepatobiliary and Pancreatic Diseases, Zhengzhou University, Zhengzhou 450052, China.

Ye Li (Y)

Department of Pathology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.

Chi-Xian Zhang (CX)

Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China; Zhengzhou Key Laboratory of Hepatobiliary and Pancreatic Diseases, Zhengzhou 450052, China; Institute of Hepatobiliary and Pancreatic Diseases, Zhengzhou University, Zhengzhou 450052, China.

Wei-Jie Wang (WJ)

Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China; Zhengzhou Key Laboratory of Hepatobiliary and Pancreatic Diseases, Zhengzhou 450052, China; Institute of Hepatobiliary and Pancreatic Diseases, Zhengzhou University, Zhengzhou 450052, China.

Ruo-Peng Liang (RP)

Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China; Zhengzhou Key Laboratory of Hepatobiliary and Pancreatic Diseases, Zhengzhou 450052, China; Institute of Hepatobiliary and Pancreatic Diseases, Zhengzhou University, Zhengzhou 450052, China.

Jian Li (J)

Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China; Zhengzhou Key Laboratory of Hepatobiliary and Pancreatic Diseases, Zhengzhou 450052, China; Institute of Hepatobiliary and Pancreatic Diseases, Zhengzhou University, Zhengzhou 450052, China.

Kai Bai (K)

Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China; Zhengzhou Key Laboratory of Hepatobiliary and Pancreatic Diseases, Zhengzhou 450052, China; Institute of Hepatobiliary and Pancreatic Diseases, Zhengzhou University, Zhengzhou 450052, China.

Yu-Ling Sun (YL)

Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China; Zhengzhou Key Laboratory of Hepatobiliary and Pancreatic Diseases, Zhengzhou 450052, China; Institute of Hepatobiliary and Pancreatic Diseases, Zhengzhou University, Zhengzhou 450052, China. Electronic address: ylsun@zzu.edu.cn.

Classifications MeSH